EBIT: Income before interest and taxes.
Crescent Biopharma, Inc. (CBIO) had EBIT of $-39.91M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$3.12M |
|
$-37.73M |
|
-- |
|
$3.12M |
|
$43.02M |
|
$-39.91M |
|
$2.18M |
|
$-37.73M |
|
$-37.73M |
|
$-37.73M |
|
$-37.73M |
|
$-37.73M |
|
$-37.73M |
|
|
EBIT |
$-39.91M |
$-39.84M |
|
39.06M |
|
39.06M |
|
$-0.90 |
|
$-0.90 |
|
| Balance Sheet Financials | |
$295.21M |
|
$0.81M |
|
$4.29M |
|
$299.50M |
|
$23.49M |
|
-- |
|
$1.73M |
|
$25.22M |
|
$270.28M |
|
$274.28M |
|
$274.28M |
|
38.18M |
|
| Cash Flow Statement Financials | |
$-55.34M |
|
$-6.39M |
|
$138.00M |
|
$213.30M |
|
$289.58M |
|
$76.28M |
|
$12.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.57 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1280.30% |
|
-1280.30% |
|
-- |
|
-1210.33% |
|
-1210.33% |
|
$-53.73M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-13.96% |
|
-13.75% |
|
-12.60% |
|
-13.75% |
|
$7.18 |
|
$-1.38 |
|
$-1.42 |
|